Biogen, AbbVie withdraw MS drug Zinbryta globally, halt trials

Biogen Inc. (NASDAQ:BIIB) and partner AbbVie Inc. (NYSE:ABBV) will withdraw multiple sclerosis drug Zinbryta daclizumab globally from the market following eight European cases of inflammatory brain disorders, including encephalitis and meningoencephalitis. The partners are

Read the full 344 word article

User Sign In